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Prevalence of ovarian cancer and recurrent 
ovarian cancer in the UK
Ovarian cancer is the ﬁ fth most common cancer among 
women in the UK (2011), accounting for 4% of all new cases 
of cancer in females. Ovarian cancer incidence is strongly 
related to age, with the highest incidence rates being in older 
women; age-speciﬁ c incidence rates rise sharply from around 
age 35-39, peak in those aged 80-84, and subsequently plateau 
(Fig. 1). However there has been a decrease of 11% in overall 
incidence over time, probably because of the contraceptive 
pill that is known to reduce the risk of ovarian cancer [1].
Mortality rates due to ovarian cancer in the UK are 
signiﬁ cant. Ovarian cancer is the leading cause of death 
from gynaecological malignancies and is the fourth most 
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a b s t r a c t
Ovarian cancer is the 5th most common cancer found in women in the UK. It is the leading 
cause of death from gynaecological cancer, and is the 4th most common cause of cancer death 
among UK women. Similar to the majority of other cancers, relative survival rates for ovarian 
cancer are improving, although 5-year mortality rates remain stubbornly low. The stage of 
the disease at diagnosis is the single most important determinant of ovarian cancer survival, 
as many patients ﬁ rst present with advanced disease. Treatment of ovarian cancer involves 
a combination of ‘upfront’ primary surgery followed by chemotherapy. Platinum/taxane-
based chemotherapy is the recommended standard-of-care ﬁ rst-line chemotherapy, but the 
majority of patients will relapse with drug-resistant disease within 3-5 years. However, not all 
patients can continue with platinum combination therapies due to loss of activity or toxicity-
related issues, including hypersensitivity, neurotoxicity, alopecia and ototoxicity. Therefore 
the choice of second-line chemotherapy must take into account factors such as platinum-free 
treatment interval (PFI); patient’s performance status; current symptoms; history of and likely 
future toxicities while on chemotherapy; dosing schedule requirement; and cost of treatment. 
A consensus in 2010 established 4 distinct subgroups within the ROC patient population based 
on the PFI: (platinum sensitive >12 months, partially platinum sensitive 6-12 months, platinum 
resistant <6 months, and refractory disease d4 weeks). Within patients with platinum sensitive 
disease, those with partially platinum sensitive disease remain the most clinically challenging 
to manage effectively. Non-platinum based combination therapies, in particular trabectedin 
with pegylated liposomal doxorubicin (PLD), offers new options together with a signiﬁ cant 
survival advantage relative to PLD alone for these patients.
© 2014 European Organisation for Research and Treatment of Cancer. Published by Elsevier 
Limited. This is an open access article under the CC BY-NC-ND license (http://creative-
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common cause of cancer death among females in the UK 
(2011), accounting for 6% of all female deaths from cancer. 
This amounts to 13 ovarian cancer deaths for every 100,000 
females in the UK, with the highest mortality rates being in 
older women (>65 years) [1,2].
However, as with the majority of cancers, relative survival for 
ovarian cancer is improving. The latest age-standardised relative 
survival rates for ovarian cancer in the UK during 2005-2009 
show that 72.3% of women are expected to survive their disease 
for at least one year; with this ﬁ gure falling to 42.9% surviving 
ﬁ ve years or more. The relatively low ﬁ ve-year survival rates 
can be attributed partly to the fact that 29% of cases of ovarian 
cancer are emergency presentations due to the non speciﬁ city of 
symptoms. For example, data from the Anglia Cancer Network 
area for women diagnosed during 2004-08 show that ﬁ ve-year 
relative survival rates are more than 90% for early stage disease, 
but fall very sharply to less than 10% for late stage cases [1]. 
Demonstrating the importance of the stage of the disease at 
diagnosis as a determinant of ovarian cancer survival.
Nevertheless, ﬁ ve-year relative survival rates for ovarian 
cancer increased from 21% in England and Wales during 1971-
1975 to 42.9% in England during 2005-2009 (Fig. 2). It is thought 
that the signiﬁ cant increase in one-year survival is likely to 
be the result of greater use of platinum-based chemotherapy 
regimens. And the increase in ﬁ ve-year survival may be due to 
both wider access to optimal primary treatment and a greater 
determination by the clinical community to treat recurrent 
disease [3].
When UK survival rates for ovarian cancer are compared 
with those of other high income countries, including in 
Europe, they are signiﬁ cantly worse. Incidence and mortality 
rates due to ovarian cancer in the UK are on a par with Eastern 
Europe and higher than those given for Germany, France and 
Italy. Differences in data quality and coding practices may 
contribute to some of the variation, but the consistently lower 
levels for the UK suggests real differences in survival, which 
demand further investigation and earlier access to specialist 
care and improved treatment options for UK patients [4,5].
Management of patients with ovarian cancer
Treatment of ovarian cancer involves a combination of surgery 
and chemotherapy. ‘Upfront’ primary surgery for complete 
resection if possible or cytoreductive surgical debulking for 
advanced disease, followed by chemotherapy remains the 
international standard of care. Chemotherapy, however, has 
been principally responsible for the improved survival seen 
over the past 10 years [3,6].
As previously described platinum combination (typically 
platinum-paclitaxel) chemotherapy has been established as 
the standard of care following surgery for ovarian cancer [7].
Management of patients with recurrent ovarian cancer
For relapsing patients with recurrent disease, relatively few 
phase III studies have been conducted and these have been 
primarily in patients with platinum-sensitive (PS) disease. 
The International Collaborative Ovarian Neoplasm 4 (ICON-4) 
trial was the ﬁ rst to show that a combination of platinum 
and paclitaxel was more effective than single-agent platinum 
compounds in patients with relapsing PS ovarian cancer. 
The carboplatin/paclitaxel combination increased PFS by a 
median of 3 months (12.0 vs. 9.0 months; p=0.0004) and OS by 
5 months (29.0 vs. 24.0 months; p=0.02) when compared with 
carboplatin alone. [8] By comparison, the Intergroup study 
by Pﬁ sterer et al. showed that a gemcitabine/carboplatin 
combination was associated with a median improvement in 
PFS of 2.8 months (8.6 vs. 5.8 months; p=0.0031) in patients with 
PS disease, but with greater toxicity and no improvement in 
OS (18.0 vs. 17.3 months) and QoL compared with carboplatin 
alone [9]. And, the large phase III CALYPSO trial showed that 
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Prepared by Cancer Research UK - original data sources are available from 
http://www.cancerresearchuk.org/cancer-info/cancerstats, August 2014
Fig. 1 – Ovarian cancer: average age of new cases per year and age-speciﬁ c incidence rates per 100,000 population, females, 
UK (2009-2011).
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a combination of PLD and carboplatin produced a modest 
improvement in median PFS, and was a less toxic alternative to 
the standard regimen of carboplatin and paclitaxel in relapsing 
PS patients. However, no statistically signiﬁ cant difference was 
observed in OS (30.7 vs. 33.0 months; p=0.94) [10,11].
Segmentation of the ROC patient population to help tailor 
therapeutic strategies at relapse
A consensus was established in 2010 at the 4th Ovarian 
Cancer Consensus Conference of the Gynecological Cancer 
InterGroup (GCIG) held in Vancouver on issues critical to 
conducting large randomised trials, including in the ROC 
patient population [12]. One of the key questions debated 
was “How do we deﬁ ne distinct patient populations in need 
of speciﬁ c therapeutic approaches?” which can then be used 
across all relevant trials to help tailor therapeutic strategies 
for these patients.
The platinum-free interval (PFI) was deﬁ ned at the meeting 
as the interval from the last date of platinum dose until 
documented progressive disease. Participants at the meeting 
also identiﬁ ed four distinct patient populations that require 
speciﬁ c therapeutic approaches (Fig. 3) [12].
Optimisation of treatment strategies for patients with ROC 
based on platinum-free interval
It is worth bearing in mind that the ICON-4, Intergroup 
and CALYPSO studies were conducted before the recent 
stratiﬁ cation of the ROC patient population was fully deﬁ ned. 
Therefore analyses of responses in the clinically challenging 
partially platinum-sensitive (PPS) subgroup of patients were 
not performed. Until 2010, patients were typically classiﬁ ed as 
being either platinum sensitive (PS) relapsing after >6 months 
from last platinum treatment, or platinum resistant (PR) 
relapsing <6 months after previous platinum, according to the 
platinum-free interval. The ROC patient population has now 
been stratiﬁ ed as being either PS; relapsing after 12 months 
or more, PPS; relapsing within 6-12 months, or PR; relapsing 
within <6 months, to optimise treatment approaches for the 
different groups. (This will be discussed in more detail in the 
article by Professor Nicoletta Colombo).
For patients with platinum sensitive disease, platinum/
taxane-based chemotherapy is recommended in most cases, 
yet despite high sensitivity to platinum-based chemotherapy 
the majority of patients with ovarian cancer will relapse 
with drug-resistant disease within 3-5 years. Carboplatin-
based combination regimens are the backbone of treatment 
for those patients who have a late relapse (>12 months), 
producing clinical beneﬁ t with higher rates for progression-
free and overall survival. However for patients with PPS or 
PR disease, and also those who are unsuited to platinum, the 
decision for second-line treatment is far more complex with 
several additional factors needing to be considered (see Box 
1). Patients in the PPS subgroup remains the most clinically 
challenging to manage effectively, however non-platinum 
based combination therapies, in particular trabectedin+PLD, 
offers new hope together with a signiﬁ cant survival advantage 
for these patients.
Incidence of patients unsuited to receive platinum 
second-line
Not all patients can continue with platinum at second-line 
or subsequent relapses due to loss of activity or toxicity-
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Fig. 2 – Ovarian cancer, age-standardised ﬁ ve-year relative survival rates, England and Wales 1971-1995, England 1996-2009. 
*Survival rates are for England only from 1996 onwards.
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related issues including hypersensitivity, neurotoxicity, alo-
pecia and ototoxicity. In particular, hypersensitivity reactions 
(HSRs) to carboplatin are a concern and have been reported 
in approximately 15-20% of women receiving the drug [13]. 
Other authors report even higher rates, with carboplatin 
responsible for up to approximately 27% of HSRs, and 
approxi mately 50% of initial HSRs occurring during the eighth 
course of treatment. HSRs usually start within 30 minutes 
of infusion and despite premedication with dexamethasone 
and antihistamines. Other anti-neoplastic drugs can also 
lead to HSRs with varying rates (paclitaxel/docetaxel: 10-30%; 
cabazitaxel: 0.3-1.8%; cetuximab: 16-19%; trastuzumab: 40%; 
rituximab: 77%) [14-18]. The retreatment interval has also 
been shown to be important with regard to carboplatin-related 
HSRs. A retreatment interval >23 months has been associated 
with a 36% incidence of HSRs, compared with a HSR incidence 
of 8% with a retreatment interval <23 months [14].
Potential solutions for managing HSRs include skin testing to 
identify high-risk patients, and gaining a clear understanding 
of the characteristics of HSRs in an individual patient in order 
to potentially perform rapid drug desensitization (RDD). RDD 
involves administering gradually increasing small doses 
to complete the total therapeutic dose of drug allergens. 
Although no molecular target has been found for speciﬁ c 
desensitization, RDD doses induce mast cell tolerisation 
to the antigen. In order to reduce platinum HSRs, 12-16 
step administration protocols and/or dose dilution can be 
undertaken, albeit with signiﬁ cant challenges in terms of 
associated burden on nursing and resource requirements, 
and patient preference. Successful desensitisation protocols 
are usually time-consuming [15,19]. Risks and beneﬁ ts of 
desensitisation protocols must be carefully weighed, and 
patients should be informed of the danger as there is still a risk 
of anaphylaxis or even death during the platinum rechallenge 
[20,21]. Currently there is no national UK protocol on how to 
manage HSRs. Many centres ﬁ nd RDD protocols too onerous to 
utilise practically as management options, and other therapy 
options including non-platinum treatment alternatives that 
reduce the risk of HSRs should be considered.
As previously stated, platinum-based therapies can cause 
signiﬁ cant adverse events in patients, including hyper-
sensitivity, neurotoxicity, alopecia and ototoxicity. (The 
impact of these will be discussed in more detail in the 
article by Professor Christina Fotopoulou.) If platinum-based 
regimens are not possible then alternative forms of treatment 
are required.
Recently, research efforts are being directed towards the 
development of effective non-platinum based therapies. Such 
therapies aim to reduce the risk of platinum-related HSRs as 
well as to allow patients time to recover from the well-known 
adverse events associated with platinum therapies, whilst 
at the same time effectively limiting the progression of their 
disease. Trabectedin + PLD has been shown to be an effective 
non-platinum alternative treatment option [13].
Factors to consider when deciding second-line 
treatment options for patients with ROC in the UK
The choice of second-line therapy is a complex decision 
analysis, and there are several factors to consider when 
deciding second-line treatment options with these patients. As 
highlighted in Box 1, the choice of second-line chemotherapy 
must take into account factors such as: the platinum-free 
treatment interval; the patient’s performance status; their 
current symptoms; their history of and likely future toxicities 
while on chemotherapy; dosing schedule requirement; and, 
ﬁ nally, cost of treatment [22].
Box 1 – Choice of second-line chemotherapy depends 
on the following factors:
• platinum-free interval (PFI)
• patient’s performance status
• current symptoms
• history of prior toxicity on chemotherapy
• anticipated future toxicities of chemotherapy
• dosing schedule
• cost
Distinct patient population for clinical trial enrolment may be considered by interval from last platinum 
therapy.
Each trial will need to specify how they define the date of progression (CA-125 alone, radiological, 
symptomatic).
The following subgroups should be considered:
1. Progression while receiving last line of platinum-based therapy or within 4 weeks of last
 platinum dose.
2. Progression-free interval since last line of platinum of greater than 1 mo. and less than 6 mo.
3. Progression-free interval since last line of platinum of 6-12 mo.*
4. Progression-free interval since last line of platinum greater than 12 mo.*
The PFI is defined from the last date of platinum dose until PD.
Document whether patient had maintenance/consolidation therapy - which agent and for how long.
Document histological type, molecular markers such as BRCA mutation status and surgery for recurrent 
disease.
*For this group, a platinum-based combination therapy should be the control arm for randomized trials.
C2: Consensus Statement
Fig. 3 – How to deﬁ ne distinct patient populations in need of speciﬁ c therapeutic approaches? © GCIG, adapted from [12].
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Conclusions
In conclusion, despite a relatively poor long-term prognosis 
for patients diagnosed with ovarian cancer in the UK, the 
tide is begining to turn towards optimising treatment options 
for those with advanced recurrent disease. In contrast with 
ﬁ rst-line therapy where there is an excellent correlation 
between PFS and OS, this correlation is less clear for recurrent 
disease. As the majority of patients will relapse within 3-5 
years, the decision analysis for retreatment is complex. 
Consideration also has to be given to those patients with 
recurrent disease unsuited or unwilling to continue treatment 
with platinum-based therapies. Recent stratiﬁ cation of ROC 
patients according to the PFI is helping to optimise different 
therapeutic approaches for the different subgroups, and in 
particular the difﬁ cult to manage PPS subgroup. In addition, 
there is growing evidence to suggest a survival beneﬁ t 
with utilising non-platinum treatment regimens, such as 
trabectedin + PLD combination, in patients with PPS disease 
when these patients are subsequently rechallenged with 
platinum; the rationale for which will be discussed in more 
detail in the next articles.
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